Table: Santen Pharm -6-MTH group results (IFRS)
08/11/2021 06:00
Nov 8 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2021 Sep 30, 2020 Mar 31, 2022
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 128.76 118.91 260.00
(+8.3 pct) (+0.1 pct) (+4.2 pct)
Operating 18.81 18.69 41.50
(+0.6 pct) (-1.7 pct) (+240.5 pct)
Pretax 18.39 18.35 41.00
(+0.2 pct) (-0.3 pct) (+250.8 pct)
Net 14.31 13.81
(+3.6 pct) (+5.1 pct)
EPS Basic 35.79 yen 34.58 yen 77.07 yen
EPS Diluted 35.73 yen 34.50 yen
Ann Div 28.00 yen 32.00 yen
-Q2 Div 16.00 yen 14.00 yen
-Q4 Div 14.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T